B. Metzler Seel. Sohn & Co. Ag Biomarin Pharmaceutical Inc Transaction History

B. Metzler Seel. Sohn & Co. Ag

$9.49 Billion
Q2 2024

A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 7,435 shares of BMRN stock, worth $524,762. This represents 0.01% of its overall portfolio holdings.

Number of Shares

7,435

Previous 7,216 3.03%

Holding current value

$524,762

Previous $630,000 2.86%

% of portfolio

0.01%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$74.43 - $92.22 $16,300 - $20,196	219 Added 3.03%	7,435 $612,000
Q1 2024 May 15, 2024	SELL	$83.81 - $99.0 $192,763 - $227,700	-2,300 Reduced 24.17%	7,216 $630,000
Q3 2023 Nov 13, 2023	BUY	$85.07 - $94.48 $121,650 - $135,106	1,430 Added 17.68%	9,516 $841,000
Q2 2023 Aug 11, 2023	SELL	$86.68 - $100.3 $5.06 Million - $5.86 Million	-58,400 Reduced 87.84%	8,086 $700,000
Q4 2022 Feb 13, 2023	SELL	$80.93 - $108.63 $159,998 - $214,761	-1,977 Reduced 2.89%	66,486 $6.88 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $4.8 Million - $5.67 Million	58,464 Added 584.7%	68,463 $5.8 Million
Q2 2022 Aug 12, 2022	BUY	$71.48 - $86.85 $307,364 - $373,455	4,300 Added 75.45%	9,999 $828,000
Q1 2022 May 10, 2022	BUY	$74.28 - $92.69 $26,889 - $33,553	362 Added 6.78%	5,699 $439,000
Q4 2021 Feb 11, 2022	BUY	$71.72 - $91.47 $382,769 - $488,175	5,337 New	5,337 $475,000

Others Institutions Holding BMRN

# of Institutions

632

Shares Held

185M

Call Options Held

1.63M

Put Options Held

1.2M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Ag, based on Form 13F filings with the SEC.

News

Stay updated on B. Metzler Seel. Sohn & Co. Ag with notifications on news.

Account

B. Metzler Seel. Sohn & Co. Ag Biomarin Pharmaceutical Inc Transaction History